A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN OTHERWISE HEALTHY ADULTS

Intervention/treatment:
MHAA4549A (RO6876802)
Medical condition:
INFLUENZA
Protocol code:
GV29893
Control number:
195664
Status:
Closed
Approved:
June 30, 2016
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT02623322
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 65 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Medical Communications
Organization
Hoffmann-La Roche
Phone:
(+41) 616878333
Sponsor
GENENTECH INC

Locations

British Columbia

Manna Research Vancouver
Vancouver, British Columbia, V6J 1S3

New Brunswick

Moncton Hospital
Moncton, New Brunswick, E1C 6Z8

Ontario

inVentiv Health Clinique
Québec, Ontario, G1P 0A2
Manna Research
Toronto, Ontario, M9W 4L6

Quebec

Q and T Research
Gatineau, Quebec, J8Y 6S9

Results

See the results from the trial NCT02623322. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?